Zoll Medical Corporation (NasdaqGS: ZOLL) announced today that the
importance of continuous, consistent chest compressions provided by
ZOLL’s AutoPulse® Non-invasive Cardiac Support Pump in the
improvement of short-term outcomes was presented in two separate poster
presentations at the American Heart Association’s Resuscitation Science
Sessions in Orlando Florida last week.
David Ghilarducci, M.D., and Cesar Aristeiguieta, M.D., Members of
the California AutoPulse Registry Steering Committee reported in a
poster presentation "The Potential for Enhanced Near-Term Outcomes
with Mechanical CPR” that registry data showed patients treated with
AutoPulse (A-CPR) had a higher return of spontaneous circulation (ROSC)
than those receiving manual CPR (M-CPR).
The California AutoPulse Quality Assurance Registry was established to
undertake data collection related to the rate of emergency department
admissions and adverse events associated with CPR provided by the
AutoPulse in conjunction with the introduction of the new mechanical CPR
device in California. More than 1,020 patients were included in the
Registry between April 2007 and June 2009 by 32 emergency medical
services agencies using the AutoPulse to provide mechanical CPR support
in California. The results revealed that adverse events were rare; only
6 A-CPR (0.8%) treated patients reported events. Overall rate of ROSC
was improved for A-CPR vs. M-CPR both in the field (31% to 21%, p=0.002)
and ROSC sustained to ED admission (25% to 18%, p=0.014).
Don Lundy, B.S., NREMT-P, and Todd McGeorge, B.A. NREMT-P of
Charleston County EMS, North Charleston, N.C. reported in
"Mechanical Chest Compressions Improve Short-Term Outcome in Patients
Requiring CPR During Transport” that patients treated with
mechanical chest compressions were more likely to achieve return of
spontaneous circulation (ROSC) during transport compared with patients
treated with manual chest compressions (CC).
The authors report that over the study period, the agency gradually
equipped their ambulances with the AutoPulse (LDB-CC) to achieve
continuous, consistent chest compressions during transport; thus, 50% of
patients were treated with LDB-CC and 50% were treated with manual CC.
Overall, 55 (11%) patients achieved ROSC for the first time during
transport and patients treated with LDB-CC were more likely to achieve
ROSC during transport than patients treated with manual CC (14.3% vs.
6.7%, p=0.005). Of the 55 patients that achieved ROSC during transport,
44 (80%) qualified for transport according to ALS termination of
resuscitation protocols.
"We are pleased to see resuscitation outcomes improve in the
pre-hospital setting where our AutoPulse is being used,” said Jonathan
A. Rennert, President of ZOLL. "The implementation of the AutoPulse in
this setting adds the advantage of continuous consistent chest
compressions while improving provider safety during transport.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including
statements regarding the future business of the Company, and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking” statements (as defined in the Private
Securities Litigation Reform Act of 1995). Because such statements are
subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include, but are
not limited to, those factors discussed in the section entitled "Risk
Factors” in the Company's Quarterly Report on Form 10-Q filed with the
SEC on August 7, 2009. You should not place undue reliance on the
forward-looking statements in this press release, and the Company
disavows any obligation to update or supplement those statements in the
event of any changes in the facts, circumstances, or expectations that
underlie those statements.
Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill
Road, Chelmsford, MA 01824-4105. ZOLL and AutoPulse are registered
trademarks of ZOLL Medical Corporation. All product names are the
property of their respective owners.
